Financial Performance - The group's consolidated revenue for the year ended December 31, 2023, was approximately HKD 1,706,600,000, an increase of 29.5% compared to approximately HKD 1,317,700,000 in 2022[8]. - The group recorded a profit after tax of approximately HKD 275,300,000 for the year ended December 31, 2023, representing a 22.1% increase from approximately HKD 225,400,000 in 2022[8]. - The gross profit for the year was HKD 1,539,293,089, with a gross margin reflecting a strong operational efficiency[178]. - The net profit for the year was HKD 275,259,617, compared to HKD 225,411,310 in the previous year, showing an increase in profitability[178]. - Basic earnings per share increased to HKD 0.4827 from HKD 0.3927 in 2022, reflecting improved earnings performance[178]. - The overall comprehensive income for the year was HKD 244,925,110, a substantial increase from HKD 66,318,478 in 2022, indicating strong financial health[178]. - The total comprehensive income for the year ended December 31, 2023, was HKD 244,925,110, compared to a loss of HKD 132,597,063 in the previous year[183]. Cash and Assets - As of December 31, 2023, the group's cash and cash equivalents amounted to approximately HKD 509,800,000, down from approximately HKD 543,500,000 in 2022[9]. - The company reported a net cash outflow from financing activities of HKD 309,924,789 for the year ended December 31, 2023, compared to HKD 169,110,470 in the previous year[157]. - The cash and cash equivalents at the end of the year were HKD 509,845,284, down from HKD 543,486,017 at the end of the previous year[157]. - Total assets amounted to HKD 2,827,558,498, with total liabilities of HKD 903,781,273, resulting in a net asset value of HKD 1,923,777,225[180]. - The company reported a significant increase in non-current assets, totaling HKD 1,582,280,872, compared to HKD 1,498,418,728 in the previous year[180]. - The total equity as of December 31, 2023, was HKD 1,923,777,225, reflecting a stable financial position[183]. Research and Development - The group has 16 research and development projects in various stages, with 4 ophthalmology projects currently in clinical stages, identified as mid-term growth drivers[6]. - The core product, Elysium®, has become a significant growth driver for the group, acquired in March 2022, including its intellectual property and marketing rights[11]. - The company holds a total of 84 patent certificates, including 63 invention patents, indicating a strong focus on innovation[194]. - The company aims to enhance its R&D capabilities and position in the ophthalmology field through a five-year development plan initiated in 2021[193]. - The company is focusing on the development of a new gel formulation of bovine alkaline fibroblast growth factor for eye use, indicating ongoing innovation in product offerings[199]. - The company is committed to improving product efficacy and safety, as evidenced by the development of preservative-free options[199]. Market Expansion and Product Development - The group is actively pursuing market expansion and new product development strategies to enhance its competitive position in the biotechnology sector[6][11]. - The group aims to expand its market presence in lower-tier cities in China and cultivate pharmacies as auxiliary sales channels[59]. - The company is expanding its product line with the introduction of lecithin-iodine complex capsules, aiming to capture a broader market segment[200]. - The company is also launching absorbable dressings, which may enhance its presence in the medical supplies market[200]. - The company is exploring new market opportunities through the introduction of various health-related products, including mouthwash for dental care[200]. Corporate Governance and Shareholder Information - The independent auditor's report confirmed that the financial statements reflect a true and fair view of the company's financial position as of December 31, 2023[140]. - The company has maintained sufficient public float throughout the review year and as of the report date[92]. - As of December 31, 2023, major shareholders include Yan Mingjie with 152,020,667 shares (26.78%) and Liu Huijuan with 153,945,667 shares (27.12%) of the company's ordinary shares[109]. - The company has proposed a final dividend of HKD 25,541,325 for the review year[75]. - The board has proposed a final dividend of HKD 0.045 per share, up from HKD 0.025 per share in the previous year, bringing the total dividend for 2023 to HKD 0.09 per share[197]. Environmental and Social Responsibility - The group is committed to creating an environmentally friendly work environment by promoting energy conservation and recycling initiatives[19]. - The company made charitable donations totaling approximately HKD 481,000 during the review period, down from HKD 983,000 in 2022[96]. - The group emphasizes the importance of human resources as a key asset and aims to continue being an attractive employer[25].
亿胜生物科技(01061) - 2023 - 年度财报